This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab (NICAP)

This study has been withdrawn prior to enrollment.
(change company strategy)
Information provided by:
Eurofarma Laboratorios S.A. Identifier:
First received: April 28, 2011
Last updated: July 24, 2015
Last verified: August 2013

Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups.

Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.

Condition Intervention Phase
Carcinoma Head and Neck Cancer Radiation: Radiation Therapy Drug: Nimotuzumab Drug: Cisplatin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck

Resource links provided by NLM:

Further study details as provided by Eurofarma Laboratorios S.A.:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 6 months ]
    Local control of disease will be measured by magnetic resonance imaging (MRI) and physical examination 6 weeks after treatment end.

Secondary Outcome Measures:
  • Complete clinical response rate [ Time Frame: 2 years ]
    Progression-free survival; Incidence of locoregional failure; Site of the first recurrence or progression; Objective response rate assessment; EORTC quality of life questionnaires assessment; Incidence of several adverse events;

Enrollment: 0
Study Start Date: November 2013
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiation therapy, cisplatin and nimotuzumab

Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.

Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week

Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)

Drug: Nimotuzumab
200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
Active Comparator: Radiation therapy and cisplatin

Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week

Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)

Radiation: Radiation Therapy
66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
Drug: Cisplatin
75 mg/m2, IV, doses every 3 weeks (a total of three doses)

Detailed Description:

This is a phase III, superiority, national, open-label, randomized, and two-arm study.

Patients' enrollment will be performed only after approval by competent regulatory authorities and it will last up to 12 months.

All patients taking part in the study must sign an informed consent. The patients will have stage III or IV, unresectable head and neck SCC, performance status 0 or 1.

Randomization and treatment assignment will be performed by a company specifically contracted for such purpose and will be per research site and disease stage, 1:1


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Aged 18 to 75 years old;
  • Histological or cytological confirmation of SCC in oral cavity, oropharynx, hypopharynx, or larynx;
  • Stages III or IV disease
  • Unresectability according to responsible surgeon or medical staff's opinion;
  • Performance status 0 or 1
  • Present indication for radiation therapy and chemotherapy treatment with cisplatin;
  • Adequate hepatic, renal and medullar functions, indicated by:
  • Life expectancy above 6 months.

Exclusion Criteria

  • Presence of nasopharyngeal, paranasal sinuses, or salivary glands carcinoma;
  • Presence of known distant metastasis;
  • Presence of any other active neoplasm or history of any tumor diagnosed in the last 5 years
  • Patients with inability to eat normally, in whom a gastric or enteral tubing was not possible at least 2 weeks before their enrollment in the study;
  • Previous treatment with chemotherapy, radiation therapy, or EGFR inhibitors of any pharmacological class;
  • Presence of serious comorbidity that, in the investigator's opinion, will put the patient at risk or will jeopardize protocol compliance;
  • Active known seropositivity for HIV, hepatitis B or C
  • Presence of a significant neurological or psychiatric disease, as per the investigator's judgment;
  • Hypersensitivity or allergy to any of the study treatments;
  • Presence of uncontrolled hypercalcemia;
  • Pregnancy or breastfeeding;
  • Female patients of childbearing potential who wish to become pregnant or are unwilling, as well as their partners, to use an appropriate contraceptive method throughout the study period;
  • Participation in any clinical trial in the last 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01345084

Hospital Erasto Gaetner
Curitiba, Paraná, Brazil, 81520-060
Hospital de Clínicas de Porto Alegre
porto Alegre, Rio Grande do Sul, Brazil, 90035-903
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil, 14784-400
Hospital Amaral Carvalho
Jau, São Paulo, Brazil, 17210-120
Centro Oncológico de Mogi das Cruzes
Mogi das Cruzes, São Paulo, Brazil, 08730-500
Hospital de Base São José do Rio Preto
São José do Rio Preto, São Paulo, Brazil, 15090-000
Hospital Federal de Bonsucesso
Rio de Janeiro, Brazil, 210041-030
Instituto do Câncer de São Paulo
São Paulo, Brazil, 01246-000
Sponsors and Collaborators
Eurofarma Laboratorios S.A.
Principal Investigator: Gustavo Girotto Hospital de Base São José do Rio Preto
  More Information

Responsible Party: Fernanda Martinez, Eurofarma Laboratórios Identifier: NCT01345084     History of Changes
Other Study ID Numbers: EF 118
Study First Received: April 28, 2011
Last Updated: July 24, 2015

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Antineoplastic Agents processed this record on June 23, 2017